New hope for mesothelioma patients: experimental drug tested in 47-person trial
NCT ID NCT05005429
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tested a drug called Bintrafusp alfa (M7824) in 47 people with advanced pleural mesothelioma that had worsened after platinum-based chemotherapy. The drug aims to block two proteins that help tumors grow. Researchers measured how long patients lived without their cancer getting worse and checked for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Bintrafusp alfa (M7824)
What this could lead to
If successful, this could offer a new treatment option for advanced mesothelioma patients who have already tried chemotherapy.
What could go wrong
This is a small, early-phase trial with only 47 participants, so results may not apply to everyone. The drug may not slow tumor growth or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MESOTHELIOMA; LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Clínico Universitario de Valladolid
Valladolid, Valladolid, 47003, Spain
-
Hospital Clínico de Valencia
Valencia, Valencia, 46010, Spain
-
Hospital General Universitario de Alicante
Alicante, Alicante, 03010, Spain
-
Hospital Parc Taulí
Barcelona, Barcelona, 08208, Spain
-
Hospital Universitari Vall d' Hebron
Barcelona, Barcelona, 08035, Spain
-
Hospital Universitario Central de Asturias
Oviedo, Oviedo, 33011, Spain
-
Hospital Universitario Fundación Jiménez Díaz
Madrid, Madrid, 28040, Spain
-
Hospital Universitario Lucus Augusti
Lugo, Lugo, 27003, Spain
-
Hospital Universitario Puerta de Hierro
Majadahonda, Madrid, 28222, Spain
-
Hospital Universitario Virgen De La Victoria
Málaga, Málaga, 29010, Spain
-
Hospital de Basurto
Bilbao, Bilbao, 48013, Spain
-
Hospitalario Universitario A Coruña
A Coruña, La Coruña, 15006, Spain
-
ICO Badalona, Hospital Germans Trias i Pujol
Badalona, Barcelona, 08916, Spain
-
ICO Girona, Hospital Josep Trueta
Girona, Girona, 17007, Spain
-
ICO Hospitalet
L'Hospitalet de Llobregat, Barcelona, 08908, Spain